patent

R&D

Competition is on the horizon for costly narcolepsy treatmen...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment.

News

EU says Teva blocked generics to MS drug Copaxone

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it

News

Supreme court throws Novartis a lifeline for Gilenya defense

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.

News

Novartis knocked back again in bid to block Gilenya generics...

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US.

News

Alexion's shares slide after Soliris patent challenge from A...

Amgen’s famously voracious legal team is living up to its reputation once again, this time with a surprise challenge on the patents surrounding Alexion’s rare diseases blockbuster, Soliris.

News